Physician profile
Patsy Buccino
NPI 1982673232
$2,053.13
in general payments reported to CMS, 2019-2025
28 companies · $956 in 2025
The $956 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.42 · 2020: $53.41 · 2021: $165 · 2022: $137 · 2023: $127 · 2024: $541 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $287.92 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $221.25 | 2023-2025 | |
| Abbvie INC. | $211.23 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.55 | 2019-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $149.06 | 2021 | |
| Corcept Therapeutics | $123.38 | 2024-2025 | Korlym |
| Lilly USA, LLC | $120.04 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $95.76 | 2024-2025 | Camzyos, Eliquis |
| Biohaven Pharmaceutical Holding Company Ltd. | $92.59 | 2022 | |
| Axsome Therapeutics, INC. | $62.93 | 2024-2025 | Auvelity |
| Exact Sciences Corporation | $61.70 | 2024 | Cologuard Collection Kit |
| Lundbeck LLC | $51.42 | 2024-2025 | Rexulti |
| Abbott Laboratories | $50.43 | 2024-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $39.85 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $32.81 | 2022-2025 | Gardasil 9, Capvaxive |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.74 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.41 | 2025 | Elaprase |
| Otsuka America Pharmaceutical, INC. | $26.68 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $25.40 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $22.74 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $18.79 | 2023 | Quviviq |
| Shield Therapeutics INC | $17.22 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.96 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $14.78 | 2024 | Gemtesa |
| Vivus LLC | $14.72 | 2025 | Qsymia |
| Novo Nordisk INC | $14.34 | 2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $14.00 | 2023 | Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $13.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patsy Buccino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.